SDC4 and diabetes mellitus: Delivery exogenous syndecan-4 could improve angiogenic therapy for ischemia in diabetes; on the contrary, decreasing the expression of syndecan-4 on the cell surface remarkably inhibited the adhesion and migration of endothelial progenitor cells 30,31.